【24h】

Surgery for thymoma.

机译:胸腺瘤的手术。

获取原文
获取原文并翻译 | 示例
       

摘要

Although thymoma is an uncommon tumor, it represents the most frequently encountered tumor of the anterior mediastinum. These tumors represent an interesting and even peculiar group of lesions by virtue of their association with paraneoplastic disorders, their relatively indolent course, and their predisposition for local recurrence. The initial treatment of choice for patients with thymoma that do not present with unresectable local or diffuse metastatic disease is complete surgical resection. The goals of surgery are complete excision of the lesion with total thymectomy and complete exploration to rule out the presence of noncontiguous disease that may be resectable. Often, complete resection may require the resection of surrounding involved structures including pericardium, pleura, lung, and even major vascular structures. Some authors have suggested VATS or VATS-assisted techniques for small thymomas. Capsular invasion, however, often can be subtle, and the completeness of resection is of prime importance in countless studies. With recurrences appearing up to 5 and even 10 years postoperatively, time will tell if these minimally invasive techniques are comparable with current standard approaches. Multiple studies have failed to determine conclusively the role of induction chemotherapy and adjuvant radiation. Prospective multi-institutional trials are required to elucidate further the role of such therapies in these rare tumors. In the interim, the authors continue to recommend postoperative radiation for all patients undergoing resection with the exception of stage I patients. Some promising reports on response to chemotherapy have led them to develop an induction chemotherapy protocol for patients with clinically advanced disease.
机译:尽管胸腺瘤是一种罕见的肿瘤,但它代表了最常见的前纵隔肿瘤。这些肿瘤由于与副肿瘤性疾病,相对缓慢的病程和局部复发的易感性有关,因此代表了一组有趣的甚至独特的病变。对于没有不可切除的局部或弥漫性转移性疾病的胸腺瘤患者,首选的治疗方法是完全手术切除。手术的目标是通过全胸腺切除术彻底切除病灶,并进行全面探索以排除可能切除的非连续性疾病。通常,完全切除可能需要切除周围的相关结构,包括心包,胸膜,肺,甚至主要的血管结构。一些作者建议使用VATS或VATS辅助技术治疗小胸腺瘤。但是,囊膜的浸润通常很细微,在无数的研究中,切除的完整性至关重要。随着术后复发出现长达5年甚至10年,时间将证明这些微创技术是否可与当前的标准方法相提并论。多项研究未能最终确定诱导化疗和辅助放疗的作用。需要进行前瞻性的多机构试验,以进一步阐明此类疗法在这些罕见肿瘤中的作用。在此期间,作者继续建议所有接受切除手术的患者(I期患者除外)进行术后放射治疗。关于化学疗法的一些有希望的报道使他们开发出了一种用于临床晚期疾病患者的诱导化学疗法方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号